Registered Dalargin and Leitragin COVID-19 trial
Completed trial · registry only · 2020
- Registered population or design
- 320 actual enrollees reported. The four arm descriptions list 80 participants apiece.
- Results availability
- The registry lists a completed 320-person Phase III trial with standard care, Dalargin, Leitragin and combination arms. No results are posted in the registry.
Reported findings and study design
The patent gives no measured outcomes
Open-label randomized parallel-group study. The registry provides actual overall enrollment and describes four planned groups.
Dose, route and schedule
All four arms received the study’s background care. The add-on arms specify Dalargin 1 mg intramuscularly daily for 10 days, Leitragin 10 mg by inhalation daily until pulmonary complications resolved, or both.
Protocol source ↗ · ClinicalTrials.gov record and sponsor-submitted enrollment and intervention fields.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Actual enrollment | 320 participants |
Arm descriptions as specified by the sponsor
| Arm | Listed group size | Study intervention alongside background care |
|---|---|---|
| Comparison | 80 | Background care only |
| Dalargin | 80 | 1 mg IM daily for 10 days |
| Leitragin | 80 | 10 mg inhaled daily until pulmonary complications resolved |
| Combination | 80 | Dalargin plus Leitragin on the same schedules |
Arm sizes in the protocol descriptions. Arm-level enrollment and outcomes are unavailable.
Source for these results ↗ · Reviewed 2026-11-15
Study limitations and source details
Study limitations
- Intervention labels and dose descriptions conflict in the registry. The arm summaries follow the detailed descriptions. The listed treatment reflects 2020 study methods.
Source details
Trial registry
ClinicalTrials.gov record and sponsor-submitted enrollment and intervention fields.
Sources checked
Citation
Burnasyan Federal Medical Biophysical Center. Registered Dalargin and Leitragin COVID-19 trial ClinicalTrials.gov NCT04346693.